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Abstract 
 
Purpose: Aseptic loosening is a major cause of premature failure of total knee arthroplasty (TKA). 
Variations in peri-prosthetic bone mineral density (BMD) and osteoimmunological biomarkers 
levels could help to quantify prosthesis osteointegration and predict early aseptic loosening. 
Methods: The gene expression of five selected osteoimmunological biomarkers was evaluated in 
tibial plateau bone biopsies by Real Time PCR and changes in their serum levels after TKA were 
prospectively evaluated with enzyme-linked immunosorbent assays for one year after surgery. 
These variations were correlated to changes in peri-prosthetic bone mineral density (BMD). 
Results: Sixteen patients were evaluated. A statistically significant decrease in serum levels of 
Sclerostin (p=0.0135) was observed immediately after surgery. A specular pattern was observed 
between DKK-1 and OPG expression. No statistically significant changes were detectable in the 
other study biomarkers. Peri-prosthetic BMD did not change significantly across the duration of the 
follow-up. 
Conclusion: Prosthetic knee surgery has an impact on bone remodelling, in particular on SOST 
expression. Although not showing statistically significant changes, in the patterns of DKK-1, OPG 
and RANKL symmetries and correspondences related to the biological activities of these proteins 
could be identified. Variation in osteoimmunological biomarkers after TKA surgery can help in 
quantifying prosthesis osteointegration. 
 
Keywords 
Osteoimmunology; Biomarker; Bone mineral density; Total knee replacement; Sclerostin; 
Osteointegration 
 
Level of Evidence: Prospective cohort study, level II. 
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1.  Introduction 
 
Total knee arthroplasty (TKA) has proven to be a safe and effective surgical treatment for patients 
with advanced knee osteoarthritis. Despite improvements in prosthetic design and surgical 
techniques, aseptic loosening resulting from osteolysis or peri-prosthetic bone loss is a major cause 
of premature failure of prosthetic knee surgery. The diagnosis of early aseptic loosening is based on 
clinical and radiographic evaluation, but biomarkers are currently gaining interest for the 
preoperative differentiation between septic and aseptic loosening (1).  
Numerous evidences in the literature confirmed differences in biomarker levels in patients 
undergoing prosthetic revision surgery when compared to levels of the healthy population or 
patients with stable implants. Only a small number of clinical studies have assessed the pre-
operative status of bone metabolism or evaluated post-operative changes in biomarker levels. 
Collecting these data could help to estimate the risk of aseptic loosening even before implantation 
of the first prosthesis (1–3). 
In the past decade, a growing attention has been directed to osteoimmunological factors, which are 
soluble mediators linking bone tissue to immune system (4,5). However, no studies described the 
changes in these proteins after implantation of a TKA and related them to densitometric studies in 
the attempt to provide a predictive information on osteointegration. 
The ligand of the receptor activator of nuclear factor kappa-B (RANKL) is considered the main 
osteoimmunological marker, together with its receptor and the decoy receptor Osteoprotegerin 
(OPG) (6). RANK is a membrane-bound receptor, but it can be found also in the serum. Osteoblasts 
produce RANKL and OPG to regulate the differentiation of the osteoclasts, which express RANK 
(7). Sclerostin (SOST) and Dickkopf-related protein 1 (DKK-1) are two inhibitors of the Wnt 
pathway, which plays a crucial role in bone remodelling. By inhibiting Wnt signalling, these 
molecules reduce osteoblast activity (8–10).  
The aim of this study was to analyse the variation in osteoimmunological biomarkers after TKA 
surgery and compare them with radiological and clinical signs of mobilisation, in order to quantify 
prosthesis osteointegration and predict early aseptic loosening. 
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2. Materials and methods 
 
The primary goal of this prospective observational clinical trial was to measure changes in 
expression of five selected osteoimmunological biomarkers after implantation of a TKA: Dickkopf-
related protein 1 (DKK-1), Sclerostin (SOST), Osteoprotegerin (OPG), Receptor activator of 
nuclear factor kappa-B (RANK) and its ligand (RANKL). Secondary goal was to relate these 
changes with variations in peri-prosthetic bone mineral density (BMD) and clinical short-term 
results. The study protocol was approved by the Regional Ethical Committee (authorization number 
2787) and registered at ClinicalTrials.gov (NCT01971931).  
Patients were prospectively enrolled by two investigators, according to inclusion and exclusion 
criteria listed in Table 1. 
All patients underwent clinical examination, long-leg and standard knee radiographs. Prior to the 
surgery (T0), blood samples were collected for determination of the serum protein levels of the 
aforementioned osteoimmunological markers and Interleukin-6 (IL-6), and each patient was asked 
to fill out the Oxford Knee Score (OKS) questionnaire and the Visual Analogue Scale (VAS) 
evaluation tool. 
A cemented, posterior stabilised, mobile bearing, prosthesis with patellar resurfacing (P.F.C. Sigma, 
DePuy International, England) was implanted using a medial parapatellar approach by the same 
senior surgeon in all patients. During surgery, a bone biopsy of the tibial plateau, as close as 
possible to the final prosthetic site, was collected for determination of DKK-1, SOST, OPG, 
RANK, RANKL and IL-6 mRNA expression levels. The retro transcription phase was performed 
using 1 μg of total RNA, according to the manufacturer’s instruction of the ProtoScript® First 
Strand cDNA Synthesis Kit for RT-qPCR system (New England BioLabs Inc.). All samples were 
retrotranscripted 3-5 min using Thermo cycler (Perkin Elmer, 2400 Gene Amp PCR System, 
Germany) Quantitative PCR was performed using commercial TaqMan
®
 Gene Expression Assay 
(Life Technologies Italia, Monza), according to the manufacturer’s instruction; The fold change in 
expression of the different genes in patients was normalized to the expression of 18s. The accuracy 
was monitored by the analysis of the melting curves. 
IL-6, DKK-1 and SOST were measured in serum using ELISA sandwich Quantikine Assays, while 
OPG, RANK and RANKL were measured using an ELISA Duo Set Assay, (R&D Systems, 
Minneapolis, MN, USA), according to manufacturer’s protocols. 
No metallic staples were used for wound closure to avoid interference with peri-prosthetic Dual 
Energy X-ray Absorptiometry (DXA) measurements. Anaesthetic, pain-control medications, 
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antithrombotic and antibiotic prophylaxes and rehabilitation procedures were standardised 
according to the institution’s internal protocols (Appendix 1).  
A peri-prosthetic DXA of the operated knee were obtained on the 4
th
 post-operative day (T1) and 
three (T2), six (T3) and twelve months (T4) after surgery. Peri-prosthetic DXA protocol and 
determination of the regions of interest (ROI, figure 1) are presented in Appendix 2 (11,12). All 
imaging studies were evaluated by a single clinical radiologist. Blood sample for determination of 
the serum protein levels of the aforementioned markers and IL-6 were collected at T1, T2 and T4. 
OKS and VAS were prospectively collected at T2, T3 and T4 and the Forgotten Joint Score (FJS) at 
final follow-up (T4) (13). All protocols for biomarkers identifications are described in the Appendix 
3. 
Statistical analysis was performed using GraphPad Prism v 6.0 software (GraphPad Software Inc.). 
Continuous variables were expressed as the mean ± standard deviation (SD), while the dichotomous 
variables are expressed in numbers of cases and frequencies. The Shapiro-Wilk normality test was 
used to evaluate the normal distribution of the sample. Evaluation of the differences between and 
within the groups was performed using one-way analysis of variance (ANOVA) followed by a two 
tailed, paired Student’s t-test or Mann–Whitney test according to the characteristics of the data 
distribution. 
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3. Results 
Nineteen patients were enrolled. One patient received non-simultaneous bilateral TKA, with a one-
year delay between interventions. Complete data were collected for 16 patients, with a large female 
dominance (4 males, 12 females); all women were in postmenopausal status. Three patients were 
excluded from due to implantation of a different prosthesis model or need for additional 
osteosynthesis of an intra-operative periprosthetic fracture. Demographic data are shown in Table 2. 
 
3.1 Evaluation of mRNA expression in bone biopsies (T0) (Table 3) 
The biomarker gene expression displayed a great variability among patients, as shown by a quite 
high SD, but, as a general trend, the expression level was lower than the 18S expression. Among the 
biomarkers analysed, the lowest expression was observed for SOST gene and the highest for DKK-
1 gene. Mean OPG expression was higher than mean RANKL expression, and the resulting 
RANKL/OPG ratio was 0.818 ±0.293. 
 
3.2 Evaluation of serum protein levels (T0, T1, T2, T4) (Table 4, Figure 2) 
In order to estimate pre-and post-operative inflammatory status, IL-6 level was measured: pre-
operative IL-6 level was always in the reference range (14). A statistically significant increase 
(p=0.0008) was displayed at T1, followed by return to physiological levels at subsequent follow-up 
points, comparable to T0 level. 
SOST protein level was in the reference range (15) at T0. A little but statistically significant 
decrease (p=0.0135) was observed at T1, followed by return to levels comparable to T0. Since a 
difference between SOST levels between genders was previously reported (16,17), the different 
level of serum SOST was evaluated in men and women: men displayed a modestly but non-
significantly higher SOST level at T1 and T2.Whereas the level modestly but non-significantly 
higher level at T4 for women. 
The levels of DKK-1 and of the bone-protective marker OPG protein level were comparable to the 
reference range (18,19)  at T0 and, showed non-significant oscillations in the subsequent follow-up 
points. A specular pattern of was observed between the oscillating expression of these two 
biomarkers at all time points. 
RANK protein level was in the reference range at T0 and displayed a statistically non-significant 
decrease at T1, followed by an increase in the subsequent follow-up points. 
RANKL protein level could be detected only in seven patients and was always in the reference 
range (19) at T0. At T1, it showed a little and non-significant decrease, whereas at T2 and T4 it 
displayed a little and non-significant increase. The fact that some subjects can have free RANKL 
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levels below the limit of detection is described (20). This is due to the fact the majority of 
commercial kits available measure free RANKL, which represent 1/1000
th
 of the total RANKL 
(21). 
In order to better define the bone resorption status, the RANKL/OPG ratio was evaluated. At T0 
RANKL/OPG ratio was 0.45 (± 0.57).  An increase, even though not statistically significant, was 
observed in the subsequent follow-up points. 
 
3.3 Evaluation of BMD (T1, T2, T3, T4) 
Pre-operative DXA revealed normal BMD in 12.5% of the patients and reduced BMD values in the 
remaining study population (T-scores: lumbar: -0.5 ± 2.5; femur, right: -0.8 ± 1.1; femur, left: -0.9 
± 1.1). Average BMD in the different regions investigated did not show any significant reduction 
across the duration of the follow-up (Figure 3). A trend towards increasing BMD was registered in 
the R1 and R3 zones, whereas a moderate decrease was registered in R2 and R5. Average BMD 
variation in R4 showed a decrease > 1% across the study period. None of the recorded variations 
appeared to reach statistical significance. We found a comparable rate of variation in BMD values 
during time between periprosthetic cortical areas (ROI 1 to 4) and periprosthetic trabecular area 
(ROI 5), as well as between males and females. Considering all the ROI, women had a minimal 
reduction of BMD compared to baseline (overall reduction= -0.66%), while this difference was 
almost negligible with males (overall reduction= -0.09%). 
 
3.4 Clinical and functional evaluation (T1, T2, T3, T4) 
Pre-operative OKS was 19.44 (± 8.11) points and VAS 6.5 (± 2.92) points. A statistically 
significant increase in OKS (p<0.0001), associated to decrease in VAS (p<0.0001) was registered 
(Figure 4). At final follow-up average FJS was 61.15 (± 23.49) points. No cases of implant failure 
or prosthetic loosening were recorded. 
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4. Discussion 
 
The main finding of this study is that a statistically significant decrease in SOST expression occurs 
shortly after TKA, followed by a steadily increase. This innovative finding confirms the hypothesis 
that prosthetic knee surgery has an impact on bone remodelling and osteointegration. No 
statistically significant changes occured in the expression of the other biomarkers following TKA 
implantation, but symmetries and correspondences in the patterns of DKK-1, OPG and RANKL 
could be identified. 
DXA was not capable to detect BMD changes on both sides of the prosthesis and no significant 
correlation between biomarkers levels and clinical or radiological outcomes could be identified, 
indicating that bone remodelling occurs without visibly affecting the postoperative course after 
TKA.  
Bone quality and prosthesis osteointegration are relevant for long-term success of primary TKA. 
Lack of integration may lead to aseptic loosening. For this reason, previous research was directed to 
the clinical relevance of biomarkers evaluating bone remodelling, being placed in relation to the 
clinical outcomes in orthopaedic surgery (22–24). 
Using these bone remodelling biomarkers permits to monitor bone turnover with high sensitivity 
and specificity, since the serum concentration of these molecules is proportional to their activity in 
bone tissue. Moreover, serum investigation has minimal discomfort for the patient and does not 
expose to radiation. For these reasons, the possibility to quantify prosthesis osteointegration and to 
predict early aseptic loosening the evaluation of these biomarkers is appealing. 
This study focuses on the role of osteoimmunological markers in bone remodelling after TKA 
implantation and highlights a characteristic trend in SOST level not described yet. In our 
population, a general low state of gene expression was encountered: this is documented in tissue 
biopsies, where all analysed genes displayed expression levels lower than the 18S, chosen as 
reference housekeeping gene. The 18S expression was stable and comparable among patients, 
therefore the low gene expression of all the biomarkers should be referred to a low 
osteoimmunological response of the bone tissue. This result is in agreement with the absence of 
significant alteration in BMD in the follow-up period. This implies that DXA was not capable to 
detect changes in BMD values that occurred on both sides of the prosthesis and suggests that in our 
patients surgery produced only minor changes to the bone metabolism, without inducing significant 
bone loss. This was clinically confirmed by the fact that no cases of aseptic loosening were 
observed in the study population. Other authors have documented changes in the peri-prosthetic 
BMD, however being not associated with any negative clinical outcome: specifically, Soininvaara, 
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Järvenpää et al. indicated that the highest bone-loss rates occurred during the first three post-
operative months after TKA, and continued around the femoral component for up to 7 years. The 
clinical outcome, ass quantified by the improvement in a functional score, was not associated with 
peri-prosthetic BMD change (11,12,25). A variable prosthesis-related stress-shielding and different 
patient’s muscle mass could be possible explanations to these differences, as proposed Mau-Moeller 
et al. after comparing DXA, muscle mass and strength ten days and three months after surgery in 23 
patients undergoing TKA (26). 
Tissue gene expression gives only a partial information about bone metabolism, since 
osteoimmunological markers can be regulated at post-translational level. For this reason, the 
circulating concentration of the osteoimmunological markers was evaluated (Table 3). 
Our study demonstrated that typical serum expression patterns could be identified after TKA for  
SOST, which showed an initial decrease, followed by a steadily increase at later follow-up points. 
However, the pre-operative values appeared not to be predictive of post-operative changes. RANK 
receptor displayed a stable level before and after surgery, suggesting that prosthetic procedures did 
not alter neither the expression not the production of this molecule. 
SOST promotes the RANKL-dependent osteoclast formation and osteocyte activity (27), while 
DKK-1 induce the production of RANKL, thereby shifting the balance of RANKL/OPG in favour 
of RANKL and promoting osteoclastogenesis and bone resorption (28,29). In our series, DKK-1 
displayed no significant changes; consistently, a parallelism in the RANKL trend was observed, 
which could be promoted by the early stimulus of DKK-1. Being DKK-1 a negative regulator of 
OPG (30), the expression of DKK-1 could explain the specular pattern observed for OPG, resulting 
in a net increase of RANKL/OPG ratio. 
A growing attention has been focused on the relationship between the serum levels and 
corresponding levels in bone for these important osteoimmunological molecules, OPG and RANKL 
(21). The first reason for this interest is that the ratio of RANKL mRNA to OPG mRNA 
(RANKL/OPG ratio) has been shown to correlate with osteoclast surface, a reliable measure of 
bone resorption (31). The second reason is that circulating OPG and RANKL could have different 
cellular sources, as part of a negative feedback system. In particular, an inverse relationship was 
observed between RANKL mRNA and serum RANKL, suggesting that the shedding activity of 
RANKL into the circulation is decreased with increasing expression of RANKL mRNA (21).  
Soluble RANKL has been described as a predictor of non-traumatic fracture risk, in particular with 
low levels of serum RANKL having been associated to a lower degree of bone remodelling (32). In 
our patients, RANKL showed a light trend of increase from T1 to following time points, suggesting 
that bone recovery after surgery is occurring, and potentially reducing non-traumatic fracture risk. 
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The fact that no correlation could be found between BMD and RANKL in our series is in agreement 
with previous reports showing that serum RANKL could be a fracture risk predictor unrelated to 
bone mass assessment (32). 
The interpretation of serum OPG is debated: some authors indicate high serum OPG as an indicator 
of increased osteoblast activity, therefore bone production, whereas some others OPG increase as a 
response to elevated bone turnover in order to counter excessive bone resorption (33). Among our 
patients, a single case of significant OPG decrease after surgery was observed; interestingly, this 
was the only patient who also presented a more pronounced reduction of peri-prosthetic BMD, 
suggesting a relevant role of OPG in the bone formation process. 
The RANKL/OPG ratio is considered a better indicator of bone turnover status than RANKL and 
OPG taken separately. RANKL/OPG ratio has been observed to correlate with BMD changes, 
suggesting a possible predictive role for osteolysis and fracture risk (34). In our patients, an 
increasing trend from T0 onwards was observed in RANKL/OPG ratio, indicating a shift of the 
bone formation/resorption balance towards an increase in resorption of new bone. This trend could 
not be confirmed by variations in peri-prosthetic BMD. 
Since osteoimmunological markers are influenced by inflammatory response, the inflammatory 
cytokine IL-6 was chosen to be analysed, having its expression already been related to changes in 
osteoimmunological biomarkers levels. As expected , IL-6 displayed a strong up-regulation at the 
earliest time point after surgery, confirming the physiological inflammatory response occurring 
after a surgery procedures (35). At later follow-up points, IL-6 returned to expression levels 
comparable to T0, confirming that the inflammatory response is transient and limited to the early 
post-operative period (5). 
This study has a number of limitations: the population was composed of a relatively small number 
of Caucasian, elderly patients, with a large female dominance; this could limit the statistical power 
of our conclusion and should be considered prior to extrapolating the significant findings to the 
general population. Follow-up was limited to twelve months, which is insufficient to determine the 
rate of aseptic loosening at long-term follow-up. For ethical reason, we decided not to enrol a 
healthy control group; however, biomarkers levels in analysed patients were compared to reference 
ranges already reported in literature. Finally, a single type prosthesis was used; other systems may 
affect differently the peri-prosthetic bone and these results may then not be representative for all 
different implants available. 
 
5. Conclusion 
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This study evaluated changes in expression of selected osteoimmunological biomarkers after TKA 
implantation, correlating them with variations in peri-prosthetic BMD and clinical short-term 
results. A decrease in SOST expression occurs shortly after TKA followed by a steadily increase at 
later follow-up points. Moreover, a specular pattern was observed between DKK-1 and OPG 
expression. DXA was not capable to detect BMD changes on both sides of the prosthesis. 
Variation in osteoimmunological biomarkers after TKA surgery can help in quantifying prosthesis 
osteointegration.
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Appendix 1 : standardized peri-operative procedures 
 
Antibiotic prophylaxis 
 
Perioperative antibiotic prophylaxis was routinely administrated to all patients undergoing TKA 
with Cefazolin (2g intravenous, 30 minutes before the skin incision and repeated 1g x 2 8 and 16 
hours after surgery) or Vancomycin in patients with beta lactam allergy (1g intravenous 60 
minutes before the skin incision). Prophylaxis for urinary tract infections was administrated only if 
catheterization was necessary (Gentamycin, dosing adapted to patient’s weight). 
 
Antitromboembolic prophylaxis 
 
Enoxaparin sodium 4000 IU / day, from 12 hours before surgery and, thereafter, for 35 days after 
surgery. In presence of long-term oral anticoagulation, interruption of oral anticoagulation and 
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bridging with Enoxaparin sodium after cardiologic consultation. The standard prophylactic dosage 
was adjusted for cardiac pre-existing diagnoses and adapted for weight and kidney function if 
necessary, after cardiologic or internistic consult. Bilateral compression stockings (mediven® 
thrombexin® 18, medi GmbH & Co. KG, 95448 Bayreuth, Germany) from the first day after surgery 
up to 2 months, with progressive discontinuation after 35 days after surgery. 
 
Anesthesiological protocol 
 
Combined spinal-epidural anesthesia with Bupivacaine 0.5% 10-12.5 mg (or Levobupivacaine 0.5% 
10-12.5 mg) + sedation or general anesthesia. No local intra-articular injection of anesthetics was 
performed. Monitoring: ECG, non-invasive monitoring of arterial pressure, Δ ST tract, O2 
saturation, diuresis (catheterization of patients according to age and after clinical evaluation). 
 
Blood management procedures 
 
In all patients a tourniquet was inflated before the skin incision and released before inspection of 
posterior capsular bleeding and insert placement; careful hemostasis with bipolar electrocautery 
was routinely performed after tourniquet release. One deep intra-capsular Redon type suction 
drain was used in all patients and was removed on the first or second post-operative day. One 
gram of tranexamic acid was administrated intra-venously approximately 30 min prior to 
tourniquet release and 1 g intra-articularly after fascial closure. The same compression bandage 
from the ankle to the thigh was used in all patients and substituted with compression stockings 
(mediven® thrombexin® 18, medi GmbH & Co. KG, 95448 Bayreuth, Germany) the first day after 
surgery. 
Rehabilitation procedures 
The rehabilitation procedures were standardized and included early mobilization on the first post-
operative day, after removal of the surgical drain, followed by continuous passive motion (2 + 2 
hours per day with Kinetec®, Kinetec Ltd., GU12 4RH, Hants, United Kingdom) and assisted 
isometric strengthening exercises with a physiotherapist until reaching of a minimum active knee 
range of motion of 0-90°. Deambulation with 2 crutches and full weight-bearing was allowed on 
the first post-operative day. As a common practice in the country where the study was performed, 
patients started rehabilitation in the surgical centre, and were discharged to a specialized 
rehabilitation centre five to seven days after surgery. 
Appendix 2 
Peri-prosthetic DXA - (T1, T2, T3, T4) 
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To evaluate post-operative variations in the peri-prosthetic region, a DXA of the knee was 
performed at T1, T2, T3 and T4 (C.M.). All DXA measurements were performed using a Hologic 
QDR-Discovery A densitometer (Hologic Inc., Bedford, MA, USA). 
All knee joints were scanned in the antero-posterior projection. Five different regions of interest 
(ROI) were defined to analyse peri-prosthetic BMD using metal removal software provided by the 
manufacturer, as previously described by Soininvaara et al. [11]. Two squared regions (ROI 1 and 
2) were placed in the distal metaphysis of the femur, just above the upper limit of the femoral 
component, with equal width and length. Similarly, two equal rectangular-shaped regions (ROI 3 
and 4) were placed in the proximal tibia and fibula, just below the lower limit of the tibial 
component. A fifth region (ROI 5) was placed just below the 3 and 4, to analyse tibial and fibular 
diaphysis. Figure 1 shows an example of the ROI location. Differences in the net average value 
(NET), which represents the sum of BMD values of each ROI, were also analysed. Once all ROI 
were defined, they were automatically copied onto the follow-up acquisitions using the compare 
utility, in order to reduce the variability from manual correction on data analysis.  
Appendix 3 
RNA extraction using TRI Reagent method - (T0) 
Total RNA was extracted from tibial plateau biopsies. The bone samples were transferred in a 
suitable container and the preservative reagent RNAlater
®
 (Qiagen, Düsseldorf, Germany) was 
removed. The samples were centrifuged in PBS 1X at 3000 rpm (1008 rcf) 5 min at 4 °C and the 
supernatant was discarded. To obtain nucleic acid RNA, TRI reagent solution (Sigma Aldrich, 
Missouri, USA) (1 mL) was added and the biopsies were fragmented by a sonicator with a blade, 
preserving the solution in ice, then centrifuged at 12000 rpm (16128 rcf) for 10 min at 4 °C. The 
supernatant phase containing RNA was transferred in a new tube and incubated for 5 min at room 
temperature (RT). Chloroform (200 μL) was added and incubation performed for 15 min at RT to 
achieve effective separation. A new centrifugation was performed at 12000 rpm (16128 rcf) for 15 
min at 4 °C and the resulting supernatant containing RNA was transferred in a new micro tube. 
After isopropanol addition (500 μL), the solution was gently agitated and then maintained for 10 
min at RT. Later, the samples were centrifuged at 12000 rpm (16128 rcf) for 10 min at 4 °C to 
obtain a RNA pellet from each sample. The supernatant was discarded and ethanol (75%, 1 mL) 
was added to purify the nucleic acid. The pellet was vortexed in ethanol and then centrifuged at 
14000 rpm (21952 rcf) for 5 min at 4 °C to discard the residual supernatant. The dried pellet was 
dissolved in 20 μL of sterile deionized water and the samples were analysed by spectrophotometry. 
 
RNA quality and yield: spectrophotometric quantification - (T0) 
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The samples purity and concentration were quantified using the spectrophotometer instrument 
“NanoDrop 2000” (Thermo Scientific, Massachusetts, USA). The ratios 260/280 “nucleic acid 
absorbance/protein absorbance” and 260/230 “nucleic acid absorbance/organic absorbance” were 
evaluated. In particular, in order to have a good quality RNA, the threshold for the 260/280 ratio 
was set at 1.7 and for the 260/230 ratio at 2. 
 
Gene expression: reverse transcription and Real Time PCR - (T0) 
The retro transcription phase was performed using 1 μg of total RNA, according to the 
manufacturer’s instruction of the ProtoScript® First Strand cDNA Synthesis Kit for RT-qPCR 
system (New England BioLabs Inc.). All samples were retrotranscripted 3-5 min using Thermo 
cycler (Perkin Elmer, 2400 Gene Amp PCR System, Germany) by means of the following program: 
amplification and real-time data acquisition were performed using the followed cycle conditions: 
initial denaturation at 95 °C for 10 min, followed by 40 cycles of 15 s at 95 °C, and 60 s at 60 °C. 
Quantitative PCR was performed using commercial TaqMan
®
 Gene Expression Assay (Life 
Technologies Italia, Monza), according to the manufacturer’s instruction; mRNA was amplified 
using the following primers: DKK-1 (Hs00183740_m1 Life Technologies California, USA), SOST 
( Hs00383602-m1 Life Technologies California, USA), OPG (Hs00900358_m1 Life Technologies, 
California, USA), RANK (Hs00187192_m1, Life Technologies California, USA), RANKL 
(Hs00243522_m1, Life Technologies California, USA), and IL-6 (Hs00985639 _m1 Life 
Technologies California, USA). The 18s (Hs03928985_g1 Life Technologies, California, USA) 
housekeeping gene was used. 
The fold change in expression of the different genes in patients was normalized to the expression of 
18s. The results obtained are the increase (or decrease) of the target gene in the bone tissue. 
Therefore, the results for upregulated and downregulated genes compared to 18s expression are > 0 
and < 0, respectively. 18s expression did not change significantly among patients. The accuracy was 
monitored by the analysis of the melting curves. 
 
Enzyme-linked immunosorbent assays (ELISA) - (T0, T1, T2, T4) 
IL-6, DKK-1 and SOST were measured in serum using ELISA sandwich Quantikine Assays, while 
OPG, RANK and RANKL were measured using an ELISA Duo Set Assay, (R&D Systems, 
Minneapolis, MN, USA), according to manufacturer’s protocols. For IL-6, the sensitivity was 0.7 
pg/mL, and intra- and inter-assay coefficients of variation were 4.2% and 3.3%. For DKK-1 assay, 
the sensitivity was 4.2 pg/mL, with intra- and inter-assay coefficients of variation 4.2% and 6.0%. 
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For SOST, the sensitivity was 1.74 pg/mL, and intra- and inter-assay coefficients of variation were 
1.8% and 8.2%. 
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7. Figure legends 
 
Figure 1: Regions of interest (ROI) defined to analyse the peri-prosthetic bone mineral density 
using a metal removal software: distal metaphysis of the femur (R1 and R2), proximal tibia and 
fibula (R3 and R4), and tibial and fibular diaphysis (R5). 
 
Figure 2: Comparison of serum levels of the selected osteoimmunological biomarkers before 
surgery (T0) and four days (T1), three (T2) and twelve months (T4) after surgery. Data are 
expressed as means ± SD. Only p-values <0.05 are indicated: ***, p<0.001 as compared to T0; 
*, p<0.05 as compared to T0. 
 
Figure 3: Comparison of post-operative variations in the peri-prosthetic bone mineral density 
(BMD) four days (T1) and three (T2), six (T3) and twelve months (T4) after surgery: BMD 
variation in the femoral ROI (blue); BMD variation in the tibial ROI (red). Data are expressed as 
means ± SD.  
 
Figure 4: Comparison of clinical results before surgery (T0), and three (T2), six (T3) and twelve 
months (T4) after surgery: a) OKS variation from pre-operative level; B) VAS variation from pre-
operative level. Data are expressed as means ± SD. Only p-values <0.05 are indicated: ***, 
p<0.001; **** p<0.0001 as compared to T0. OKS: Oxford Knee Score, in points; VAS: Visual 
Analogue Scale, in mm. 
 
8. Tables 
Table1. Eligibility criteria.  
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Table1. Eligibility criteria.  
 
Inclusion criteria: 
- Patients eligible to receive a primary TKA; 
- Age < 80 years; 
- Informed consent to participation in the study. 
 
Exclusion criteria: 
- Knee deformity > 15° in varus, valgus, femoral flexion or tibial slope; 
- Pre-operative diagnosis of osteoporosis; 
- Concomitant treatment with bisphosphonates, strontium ranelate, selective estrogen 
receptor modulators, parathyroid hormone or its analogues, calcitonine or denosumab; 
- Pre-operative diagnosis of Paget disease; 
- Thyroid and Parathyroid disorders; 
- Patients with metabolic disorders, and serious comorbid conditions that could limit the 
follow-up (e.g. neoplastic diseases, immune deficiencies, hepatitis). 
 
 
 
Table 2. Patients’ demographics Data are reported as mean (± SD) or frequency/ratio. BMI: body mass index; F/M: 
female/male; R/L: right/left; n.s.: not significant. 
 
Age 70.44 (± 5.69) 
BMI 29.50 (± 5.43) 
F/M ratio 0.75/0.25 
R/L ratio 0.44/0.56 
Smokers/Non-smokers 0/1 
 
 
Table 3. mRNA expression (relative quantification/18S). Data are reported as mean (± SD). 
 
IL-6 0.245 (± 0.175) 
RANK 0.503 (± 0.177) 
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RANKL 0.478 (± 0.161) 
OPG 0.558 (± 0.302) 
SOST 0.185 (± 0.106) 
DKK-1 0.707 (± 0,145) 
RANKL/OPG 0.818 (± 0.293) 
 
 
Table 4. Serum concentration (pg/mL) of the analyzed biomarkers. Data are reported as mean (± SD) 
 
 
No. 
patients 
T0 T1 T2 T4 
IL-6 11 3.371 (± 3.643) 43.16 (± 25.32) 4.258 (± 5.308) 3.256 (± 2.174) 
RANK 14 587.6 (± 214.3) 403.1 (± 167.9) 480.9 (± 167.2) 497.2 (± 144.5) 
RANKL 6 704.5 (± 337) 681.5 (± 467.8) 752.4 (± 488.2) 796 (± 478.9) 
OPG 16 2225 (± 613.7) 2275 (± 664.5) 2178 (± 623.5) 2311 (± 366.2) 
SOST 14 258.1 (± 134.1) 194.4 (± 77.18) 240.5 (± 83.59) 267.7 (± 95.35) 
men 
 
3 202.1 (± 209.3) 195.3 (± 113.3) 217.9 (± 119.7) 208.8 (± 129.9) 
women 11 273.3 (± 115.8) 194.2 (± 71.95) 246.6 (± 77.61) 283.7 (± 84.38) 
DKK-1 
 
13 4606 (± 1580) 4288 (± 1436) 5301 (± 3575) 3919 (± 1485) 
RANKL/OPG 6 0.3444 (± 0.1736) 0.4983 (± 0.7008) 0.7533 (± 1.109) 0.3987 (± 0.2589) 
 
 
 
 
 
 
 
